港股異動丨開啟新徵程!恒瑞醫藥(1276.HK)首日上市高開近30%
恒瑞醫藥(1276.HK)今日首日掛牌上市,高開29.4%,報57港元,盤前成交16.55億港元。恒瑞醫藥此次港股IPO定價44.05港元/股,為發行價區間的最高端,共計發行2.245億股,募集約99億港元資金,成為近五年港股醫藥板塊最大IPO。此次全球發售,恒瑞醫藥獲得募集資金淨額約99億港元,計劃約75%用於研發計劃,約15%用於在中國和海外市場建設新的生產和研發設施,及擴大或升級現有生產和研發設施,約10%用作營運資金及其他一般企業用途。萬眾矚目下,已經縱橫中國醫藥產業近三十年的“老將”恒瑞醫藥,就此開啟新徵程。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.